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Abstract
Background: Genetic studies to date have not provided satisfactory evidence regarding risk polymorphisms for
cardiovascular disease (CVD). Conversely, epigenetic mechanisms, including DNA methylation, seem to influence
the risk of CVD and related conditions. Because postmenopausal women experience an increase in CVD, we set out
to determine whether global DNA methylation was associated with cardiovascular risk in this population.
Methods: In this cross sectional study carried out in a university hospital, 90 postmenopausal women without prior
CVD diagnosis (55.5 ± 4.9 years, 5.8 [3.0–10.0] years since menopause) were enrolled. DNA was extracted from
peripheral leukocytes and global DNA methylation levels were obtained with an ELISA kit. Cardiovascular risk was
estimated by the Framingham General Cardiovascular Risk Score (10-year risk) (FRS). Clinical and laboratory variables
were assessed. Patients were stratified into two CVD risk groups: low (FRS: <10 %, n = 69) and intermediate/high risk
(FRS ≥10 %, n = 21).
Results: Age, time since menopause, blood pressure, total cholesterol, and LDL-c levels were higher in FRS ≥10 %
group vs. FRS <10 % group. BMI, triglycerides, HDL-c, HOMA-IR, glucose and hsC-reactive protein levels were similar
in the two groups. Global DNA methylation (% 5mC) in the overall sample was 26.5 % (23.6–36.9). The FRS ≥10 %
group presented lower global methylation levels compared with the FRS <10 % group: 23.9 % (20.6–29.1) vs. 28.8 %
(24.3–39.6), p = 0.02. This analysis remained significant even after adjustment for time since menopause (p = 0.02).
Conclusions: Our results indicate that lower global DNA methylation is associated with higher cardiovascular risk in
postmenopausal women.
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Background
Epidemiologic data show that postmenopausal women
experience an increase in cardiovascular disease (CVD),
which could be associated with both aging and changes
in hormonal status [1, 2]. In this group, higher preva-
lence of subclinical CVD and cardiovascular (CV) risk
factors has been associated with the decline in endogen-
ous estrogen production [3–8].
Evidence indicates that CVD results from a complex
interaction between environmental and genetic factors
[9, 10]. Thus, the formula proposed by the Framingham
Heart study to calculate CV risk takes into account com-
mon behavioral, biochemical, and environmental aspects
that may contribute to the development of CVD [11, 12].
In turn, genetic studies have shown limited predictive
value of polymorphisms to explain CV risk factors [13].
This suggests that other factors might be influencing the
estimated variability of CV risk [14, 15].
In a context in which traditional explanations are not
sufficient to account for the link between disease,
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environment, and genetics, epigenetics emerges as a
framework to provide insights into the bases of disease
[16, 17]. Epigenetics – the study of heritable changes in
gene activity or function without changes in DNA se-
quence [18, 19] – is highly relevant to all disease pro-
cesses, including CVD and its related conditions [20].
DNA methylation, a major epigenetic mechanism, is the
process by which methyl groups are added to DNA, typ-
ically regulating tissue-specific gene expression, genomic
imprinting, and X chromosome inactivation [21]. DNA
methylation is established and maintained by a con-
served family of DNA methyltransferases (DNMTs), and
plays an important role in genome stability [22]. The im-
portance of DNMTs is related to de novo DNA methyl-
transferases 3a/3b (DNMT3a/3b) synthesis, which will
methylate unmethylated cytosines to induce differential
patterns of methylation in the genome of early embryos.
These patterns are subsequently copied from parental
strands into daughter strands during DNA replication by
maintenance DNMT1 [23].
Global DNA methylation may provide a broad picture of
DNA methylation changes; previous studies have shown it
to be one of the earliest molecular changes in the transition
from a normal to a diseased cell [24, 25]. Besides, global
DNA methylation has a high-throughput, is cost-effective,
and provides quantitative results [26]. Global DNA methy-
lation changes, including decreased global DNA methyla-
tion, have been associated with clinical and subclinical
CVD risk components, such as atherosclerosis, hyperten-
sion, and coronary artery disease [26–30].
Therefore, the aim of the present study was to deter-
mine whether global DNA methylation is associated with
CV risk in a sample of postmenopausal women with no
evidence of clinical disease.
Methods
Patients
This cross-sectional study was carried out at the
Gynecological Endocrinology Unit of Hospital de Clínicas
de Porto Alegre, Brazil. Ninety postmenopausal women
from a group of 97 participants described in a previous
study [31] were included in the present analysis. Seven
women from the original group were excluded because we
were unable to detect a methylation signal in their serum
samples. As previously described [31], inclusion criteria
were menopause (defined as a combination of follicle-
stimulating hormone [FSH] levels above 35 IU/L and last
menstrual period at least 1 year before the beginning of
the study), age between 45 and 65 years, and no use of
hormone therapy for at least 3 months before the enroll-
ment. Exclusion criteria were prior diagnosis of CVD,
current smoking, or a diagnosis of diabetes. The local
Research Ethics Committee from Hospital de Clinicas de
Porto Alegre approved the study, and each participant
provided written informed consent.
Study protocol
Anthropometric measurements included body weight,
height, and body mass index (BMI, calculated as the lat-
est measured weight in kilograms divided by the height
in meters squared). Blood pressure was measured twice
with a 10-min interval using an automatic blood pres-
sure monitor (HEM-742INT; Omron, Rio de Janeiro,
Brazil). Participants were in a seated position, with feet
on the floor and the arm supported at heart level.
CV risk was estimated by using the Framingham
General Cardiovascular Risk Score (10-year risk) (FRS),
which was determined, using lipids, through the on-
line interactive risk score calculator available on the
Framingham Heart Study website [32]. Participants were
stratified into two groups according to FRS: <10 % (n = 69),
representing a low risk group; and ≥10 %, representing an
intermediate/high risk group (n = 21).
Global DNA methylation assays
Venous blood samples were collected. Genomic DNA was
extracted from peripheral leukocytes using the technique
described by Miller et al. [33]. The extracted peripheral
leukocyte DNA was quantified using a NanoDrop™ 1000
Spectrophotometer (Thermo Scientific, Wilmington, DE).
Global DNA methylation levels were obtained with an
ELISA-based commercial kit (MDQ1, Imprint® Methyl-
ated DNA Quantification Kit, Sigma Aldrich, St. Louis,
MO, USA). The MDQ1 kit is a high-throughput mo-
lecular biology kit that uses a 96-well plate format to
provide accurate differential global DNA methylation.
The samples were incubated with capture and detection
antibodies and absorbance was read at 450 nanometers.
Quantification of global DNA methylation was obtained
from calculating the amount of methylated cytosines in
the samples (5 mC) relative to global cytidine (5 mC + dC)
in methylated control DNA (50 ng/μL). For each sample,
methylation analysis was performed in duplicate (200 ng
DNA each), and the average of these measurements is
reported. The intra and interassay coefficient of variation
(CV) were <10 %.
Biochemical and hormone assays
Serum estradiol, insulin, high-sensitive C-reactive pro-
tein (hs-CRP), glucose and lipid profile (triglycerides,
total cholesterol, and high-density lipoprotein [HDL]
cholesterol) were determined in a 12-hour fasting blood
sample collected between 8 and 10 a.m. and assessed by
colorimetric-enzymatic methods (Siemens Advia 1800
System, Deerfield, USA) with a coefficient of variation
(CV) <3.4 %. Low-density lipoprotein (LDL) cholesterol
was estimated indirectly using the Friedewald formula
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[34]. Serum insulin levels were measured using CLIA
(Siemens Centaur XP, Deerfield, USA), with a sensitivity
of 0.20 μIU/mL and intra- and interassay CV of 2.0 and
4.3 % respectively. Homeostatic model assessment index
(HOMA) was calculated by multiplying insulin (μIU/mL)
by glucose (mmol/L) and dividing this product by 22.5, as
previously described [35]. Estradiol was measured by
ECLIA (Roche Diagnostics, Mannheim, Germany), with an
assay sensitivity of 5.0 pg/mL and intra- and interassay
CVs of 5.7 and 6.4 % respectively. Serum hs-CRP was
assayed by nephelometric method (Dade Behring Marburg,
Marburg, Germany). Sensitivity was 0.17 mg/L and intra
and interassay CVs were 4.4 and 5.7 % respectively. For
data analysis, individual results below the sensitivity of the
assay were considered as equal to 0.17 mg/L.
Statistical analysis
Descriptive data were expressed as mean ± standard de-
viation (SD) or median and interquartile range (IQR)
(25–75 %). Variables with non-parametric distribution
were transformed into logarithms for calculation, and con-
verted back to their original form for data presentation.
Student’s t test was used for comparisons between group
means. Global DNA methylation analyses were adjusted
for time since menopause (linear regression). All analyses
were performed using the Statistical Package for the Social
Sciences (SPSS) version 20 (SPSS Inc., Chicago, IL, USA).
Findings were deemed significant at p <0.05.
Results
Considering the overall sample, mean age was 55.5 ±
4.9 years and mean BMI was 27.2 ± 4.6 kg/m2. Table 1
shows anthropometric and metabolic data for the entire
group and for each FRS group. Patients with FRS ≥10 %
were older than the group with FRS <10 %. Time since
menopause, blood pressure, total cholesterol, and LDL-c
levels were also higher in the FRS ≥10 % group in compari-
son with the FRS <10 % group. Conversely, the two groups
had similar BMI, estradiol, triglycerides, HDL-c, HOMA-
IR, glucose and high-sensitive C-reactive protein levels.
Global DNA methylation results (% 5 mC) for the overall
sample and FRS groups are also presented in Table 1. The
group with FRS ≥10 % had lower global methylation levels
compared with the FRS <10 % group (23.9 % [20.6–29.1]
vs. 28.8 % [24.3–39.6], p = 0.02), even after adjustment for
time since menopause (p = 0.02) (Fig. 1).
Discussion
In this cross-sectional study with postmenopausal
women, we found that global methylation levels were
lower in participants in the intermediate/high CV risk
group (FRS ≥10 %) as compared to those with low CV
risk (FRS <10 %). To the best of our knowledge, this is
the first study to specifically examine the association
between global DNA methylation and CV risk in post-
menopausal women with no clinical disease.
Age and time since menopause are well-known CV risk
factors [36, 37]. Indeed, decreased estrogen levels have
been implicated in the progression of atherosclerosis after
menopause [36, 37]. In addition, lifestyle is also linked to
CV risk in the menopausal transition and postmenopausal
period [38, 39]. However, in the present study, similar low
circulating estrogen levels were observed in the groups
with FRS <10 and FRS ≥10 % – despite the higher age and
time since menopause in the latter group. Also, the differ-
ences between these groups in methylation levels persisted
after adjustment for time since menopause. This observa-
tion underscores the relevance of epigenetic mechanisms
along with life style and estrogenicity for CV risk, espe-
cially in postmenopausal women.
Previous studies have associated global DNA methyla-
tion changes with clinical and subclinical CVD risk com-
ponents, such as atherosclerosis, hypertension, and
coronary artery disease, in different populations [26–30].
Global DNA methylation has been found to be lower in
hypertensive subjects than in normotensive controls,
with 5mC levels correlating with stage of hypertension
[40]. Moreover, a study analyzing long interspersed nu-
cleotide elements (LINE-1) as a surrogate marker of glo-
bal DNA methylation status in blood cells found an
association of lower methylation levels with cardiovascu-
lar events, such as stroke and ischemic heart disease in
elderly men [41]. Another study has recently reported
that lower global DNA methylation was also associated
with stroke [26]. Taken together, the results of the
present study and those produced by other investigators
suggest that global methylation status may be regarded
as a marker of CV risk in postmenopausal women. Fur-
ther studies are needed in order to better understand
the mechanisms underlying this association.
Animal studies have also shown that DNA methylation
plays a critical role in the development of atherosclerosis
and CVD. In a murine model, the absence of DNMT1
was related to increased expression of inflammatory
mediators [42]. Additionally, genetically atherosclerosis-
prone mice lacking apolipoprotein E showed changes in
DNA methylation in peripheral blood leukocytes, which
contributed to dysregulation of inflammation and pro-
motion of atherosclerosis [43]. A modest but significant
global hypomethylation status was also observed in
aortic samples, and this condition preceded any histo-
logical evidence of atherosclerosis [43].
While the predominant form of methylation occurs at
cytosines that are adjacent to guanine, separated by only
one phosphate (CpG), in the present study we also
assessed CpH sites. In this situation, a methyl group is
added to a cytosine that is upstream to an adenine, thy-
mine, or another cytosine. In fact, previous studies have
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shown that CpH methylation might be more common
than previously appreciated [44, 45]. Moreover, CpG and
CpH methylation may have distinct functions, with CpG
sites methylated symmetrically and CpH sites methyl-
ated in strand-specific fashion in introns and repetitive
DNA elements (SINE and LINE) [46].
Finally, we showed similar quantification of 5 mC
when compared with previous studies analyzing global
DNA methylation in leukocytes in different populations
[47, 48]. There is a wide range of methods to evaluate
methylation status. Recent advances in sequencing and
microarray technology make it possible to map DNA
methylation genome-wide at good resolution and in a
large number of samples [49, 50]. However, these tech-
nologies may be very expensive and data processing and
biological interpretation are still challenging [16]. Thus,
measuring methylation levels using an ELISA assay, a
well-known, simple, and reproducible technique can be
helpful to guide future studies with whole-genome bisul-
fite sequencing.
Table 1 Distribution of anthropometric and metabolic variables according to Framingham Risk Score
Characteristic Overall (n = 90) FRS <10 % (n = 69) FRS ≥10 % (n = 21) p*
Age (years) 55.5 ± 4.9 54.4 ± 4.4 59.1 ± 4.6 0.001
Time since menopause (years) 5.8 (3.0 – 10.0) 5.0 (2.5 – 9.0) 10 (4.0 – 13.2) 0.004
BMI (kg/m2) 27.2 ± 4.6 26.9 ± 4.7 28.0 ± 4.3 0.34
SBP (mmHg) 127.5 ± 17.3 120.6 ± 11.2 150.8 ± 13.5 0.001
DBP (mmHg) 78.9 ± 10.1 76.4 ± 9.2 87.3 ± 8.6 0.001
Fasting glucose (mg/dL) 93.3 ± 8.9 93.6 ± 9.1 92.1 ± 8.0 0.47
Total cholesterol (mg/dL) 216.5 ± 33.8 212.3 ± 32.7 231.0 ± 34.4 0.02
LDL-c (mg/dL) 139.2 ± 28.8 135.3 ± 27.3 152.8 ± 30.2 0.01
HDL-c (mg/dL) 53.9 ± 12.7 53.4 ± 13.2 55.5 ± 10.7 0.49
Triglycerides (mg/dL) 93.0 (72.0 – 139.7) 91.0 (70.0 – 141.2) 105.5 (75.2 – 141.0) 0.87
HOMA-IR 1.92 (1.30 – 3.19) 1.9 (1.3 – 3.2) 1.9 (1.2 – 2.9) 0.68
hs-CRP (mg/L) 1.30 (0.37 – 3.66) 1.0 (0.3 – 3.3) 2.5 (0.5 – 5.5) 0.27
Estradiol (pg/mL) 20.4 (12.0 – 31.0) 20.3 (12.0 – 31.5) 22.4 (13.4 – 30.8) 0.92
Global DNA methylation (% 5 mC) 26.5 (23.6 – 36.9)
Data are given as mean ± standard deviation or median and interquartile range (25–75 %). *p by Student’s t test, FRS <10 % vs. FRS ≥10 %
BMI body mass index, DBP diastolic blood pressure, FRS Framingham Risk Score, HDL-c high-density lipoprotein cholesterol, HOMA-IR homeostasis model assessment -
insulin resistance, hs-CRP high-sensitive C-reactive protein, LDL-c low-density lipoprotein cholesterol, SBP systolic blood pressure
Fig. 1 Percent global DNA methylation in FRS <10 and FRS ≥10 % groups. Values are expressed as median and 25–75 % IQR (lower and upper
limit of the box); maximum and minimum values are shown by the limits of vertical lines. *p = 0.02 by Student’s t test
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Limitations of the present study include the cross-
sectional design, which precludes conclusions regarding
the direction of cause and effect. Another limitation is
the relatively small sample size, which may have limited
the statistical power for some analyses, such as those re-
lated to the influence of age on the observed findings.
However, the effect sizes observed in our sample are
similar to those reported in other populations with the
same age and with established cardiovascular disease.
Conclusion
In conclusion, our results indicate that lower global DNA
methylation is associated with higher CV risk in postmen-
opausal women with no clinical evidence of disease. This
finding should be further investigated in large-scale epi-
demiological studies to assess epigenetic mechanisms of
CVD in this population.
Abbreviations
BMI: Body mass index; CV: Cardiovascular; CVD: Cardiovascular disease;
DBP: Diastolic blood pressure; DNMTs: DNA methyltransferases; FRS: Framingham
risk score; FSH: Follicle-stimulating hormone; HDL-c: High-density lipoprotein
cholesterol; HOMA-IR: Homeostasis model assessment - insulin resistance;
hs-CRP: High-sensitive C-reactive protein; IQR: Interquartile range; LDL-c:
Low-density lipoprotein cholesterol; LINE-1: Long interspersed nucleotide
elements; SBP: Systolic blood pressure; SD: Standard deviation
Acknowledgements
We thank Thais Rasia da Silva and Roberta Frantz for their support with
clinical data collection.
Funding
This work was supported by the Brazilian National Institute of Hormones and
Women’s Health/Conselho Nacional de Desenvolvimento Científico e Tecnológico
(CNPq INCT 573747/2008-3). The funding sources were not involved in study
design; in the collection, analysis and interpretation of data; in the writing of the
report; or in the decision to submit the paper for publication.
Availability of data and material
All data analyzed during this study are included in this published article.
Authors’ contributions
RBR participated in the conception and design of the study, carried out the
DNA methylation assays, was involved with data analysis and drafted the
manuscript; VF was involved with data analysis and drafted the manuscript;
SBL participated in the DNA methylation assays, was involved with data
analysis and helped to draft the manuscript; MAM was involved in the data
collection and analysis; PMS conceived the study, participated in its design
and coordination, was involved in the data analysis and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The local Research and Ethics Committee from Hospital de Clinicas de Porto
Alegre approved the study (GPPG 100317) and each participant provided
written informed consent.
Author details
1Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de
Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS
90035-003, Brazil. 2Department of Diagnostic Methods, Universidade Federal
de Ciências da Saúde de Porto Alegre, Rua Sarmento Leite, 245, Porto Alegre,
RS 90050-170, Brazil. 3Laboratory of Molecular Endocrinology, Department of
Physiology, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos,
2350, Porto Alegre, RS 90035-003, Brazil. 4Present addresses: Institute of
Cardiology of Rio Grande do Sul, Cardiology University Foundation, Avenida
Princesa Isabel, 395, Porto Alegre, RS 90040-371, Brazil. 5Unisinos University,
Av. Unisinos, 950, São Leopoldo, RS 93022-000, Brazil.
Received: 6 December 2015 Accepted: 5 October 2016
References
1. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of
coronary heart disease in women. N Engl J Med. 1987;316:1105–10.
2. Vaidya D, Becker DM, Bittner V, et al. Ageing, menopause, and ischaemic
heart disease mortality in England, Wales, and the United States: modelling
study of national mortality data. BMJ. 2011;343:d5170.
3. Davis PH, Dawson JD, Riley WA, et al. Carotid intimal-medial thickness is
related to cardiovascular risk factors measured from childhood through
middle age: the Muscatine study. Circulation. 2001;104:2815–9.
4. Koskinen J, Kahonen M, Viikari JS, et al. Conventional cardiovascular risk
factors and metabolic syndrome in predicting carotid intima-media
thickness progression in young adults: the cardiovascular risk in young
Finns study. Circulation. 2009;120:229–36.
5. Pappa T, Alevizaki M. Endogenous sex steroids and cardio- and cerebro-vascular
disease in the postmenopausal period. Eur J Endocrinol. 2012;167:145–56.
6. Stamatelopoulos KS, Armeni E, Georgiopoulos G, et al. Recently
postmenopausal women have the same prevalence of subclinical
carotid atherosclerosis as age and traditional risk factor matched men.
Atherosclerosis. 2012;221:508–13.
7. El Khoudary SR, Wildman RP, Matthews K, et al. Progression rates of carotid
intima-media thickness and adventitial diameter during the menopausal
transition. Menopause. 2013;20:8–14.
8. Lambrinoudaki I, Armeni E, Georgiopoulos G, et al. Subclinical
atherosclerosis in menopausal women with low to medium calculated
cardiovascular risk. Int J Cardiol. 2013;164:70–6.
9. Sayols-Baixeras S, Lluis-Ganella C, Lucas G, et al. Pathogenesis of coronary
artery disease: focus on genetic risk factors and identification of genetic
variants. Appl Clin Genet. 2014;7:15–32.
10. Joseph PG, Pare G, Anand SS. Exploring gene-environment relationships in
cardiovascular disease. Can J Cardiol. 2013;29:37–45.
11. Dawber TR, Meadors GF, Moore Jr FE. Epidemiological approaches to heart
disease: the Framingham Study. Am J Public Health Nations Health.
1951;41:279–81.
12. D’Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk
profile for use in primary care: the Framingham Heart Study. Circulation.
2008;117:743–53.
13. Whitfield JB. Genetic insights into cardiometabolic risk factors. Clin Biochem
Rev. 2014;35:15–36.
14. Turgeon PJ, Sukumar AN, Marsden PA. Epigenetics of cardiovascular disease - a
new “Beat” in coronary artery disease. Med Epigenet. 2014;2:37–52.
15. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of
complex diseases. Nature. 2009;461:747–53.
16. Ladd-Acosta C, Fallin MD. The role of epigenetics in genetic and
environmental epidemiology. Epigenomics. 2016;8(2):271–83.
17. Waddington CH. Canalization of development and genetic assimilation of
acquired characters. Nature. 1959;183:1654–5.
18. Heyn H, Moran S, Hernando-Herraez I, et al. DNA methylation contributes to
natural human variation. Genome Res. 2013;23:1363–72.
19. Moore LD, Le T, Fan G. DNA methylation and its basic function.
Neuropsychopharmacology. 2013;38:23–38.
20. Whayne TF. Epigenetics in the development, modification, and prevention
of cardiovascular disease. Mol Biol Rep. 2015;42:765–76.
21. Barlow DP, Bartolomei MS. Genomic imprinting in mammals. Cold Spring
Harb Perspect Biol. 2014;6:a018382. [https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3941233/pdf/cshperspect-EPI-a018382.pdf]
22. Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and
cancer. Adv Exp Med Biol. 2013;754:3–29.
23. Bestor TH. The DNA, methyltransferases of mammals. Hum Mol Genet.
2000;9:2395–402.
Ramos et al. BMC Medical Genetics  (2016) 17:71 Page 5 of 6
24. Guerrero-Preston R. Global epigenetic screening technologies: a novel tool
to address cancer health disparities in high-risk population groups. P R
Health Sci J. 2008;27:350–6.
25. Guerrero-Preston R, Herbstman J, Goldman LR. Epigenomic biomonitors:
global DNA hypomethylation as a biodosimeter of life-long environmental
exposures. Epigenomics. 2011;3:1–5.
26. Soriano-Tarraga C, Jimenez-Conde J, Giralt-Steinhauer E, et al. Global DNA
methylation of ischemic stroke subtypes. PLoS One. 2014;9:e96543.
27. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human
diseases. Biochim Biophys Acta. 2007;1775:138–62.
28. Castro R, Rivera I, Struys EA, et al. Increased homocysteine and S-
adenosylhomocysteine concentrations and DNA hypomethylation in
vascular disease. Clin Chem. 2003;49:1292–6.
29. Nanayakkara PW, Kiefte-de Jong JC, Stehouwer CD, et al. Association
between global leukocyte DNA methylation, renal function, carotid intima-
media thickness and plasma homocysteine in patients with stage 2–4
chronic kidney disease. Nephrol Dial Transplant. 2008;23:2586–92.
30. Ordovas JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev
Cardiol. 2010;7:510–9.
31. Maturana MA, Franz RF, Metzdorf M, et al. Subclinical cardiovascular disease
in postmenopausal women with low/medium cardiovascular risk by the
Framingham risk score. Maturitas. 2015;81:311–6.
32. Framingham HS. Secondary. 2015. http://www.framinghamheartstudy.org/
riskfunctions/cardiovascular-disease/10-year-risk.php.
33. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting
DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
35. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment:
insulin resistance and beta-cell function from fasting plasma glucose and
insulin concentrations in man. Diabetologia. 1985;28:412–9.
36. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship.
J Am Coll Cardiol. 2009;54:2374–5.
37. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an
age-old debate. Hypertension. 2008;51:952–9.
38. Silva TR, Alves BC, Maturana MA, et al. Healthier dietary pattern and lower
risk of metabolic syndrome in physically active postmenopausal women.
J Am Coll Nutr. 2013;32:287–95.
39. Colpani V, Oppermann K, Spritzer PM. Association between habitual
physical activity and lower cardiovascular risk in premenopausal,
perimenopausal, and postmenopausal women: a population-based study.
Menopause. 2013;20:525–31.
40. Smolarek I, Wyszko E, Barciszewska AM, et al. Global DNA methylation
changes in blood of patients with essential hypertension. Med Sci Monit.
2010;16:CR149–55.
41. Baccarelli A, Wright R, Bollati V, et al. Ischemic heart disease and stroke in
relation to blood DNA methylation. Epidemiology. 2010;21:819–28.
42. Makar KW, Wilson CB. DNA methylation is a nonredundant repressor of the
Th2 effector program. J Immunol. 2004;173:4402–6.
43. Lund G, Andersson L, Lauria M, et al. DNA methylation polymorphisms
precede any histological sign of atherosclerosis in mice lacking
apolipoprotein E. J Biol Chem. 2004;279:29147–54.
44. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base
resolution show widespread epigenomic differences. Nature. 2009;462:315–22.
45. Ramsahoye BH, Biniszkiewicz D, Lyko F, et al. Non-CpG methylation is
prevalent in embryonic stem cells and may be mediated by DNA
methyltransferase 3a. Proc Natl Acad Sci U S A. 2000;97:5237–42.
46. Guo W, Chung WY, Qian M, et al. Characterizing the strand-specific
distribution of non-CpG methylation in human pluripotent cells. Nucleic
Acids Res. 2014;42:3009–16.
47. Tellez-Plaza M, Tang WY, Shang Y, et al. Association of global DNA methylation
and global DNA hydroxymethylation with metals and other exposures in
human blood DNA samples. Environ Health Perspect. 2014;122:946–54.
48. Guerrero-Preston R, Goldman LR, Brebi-Mieville P, et al. Global DNA
hypomethylation is associated with in utero exposure to cotinine and
perfluorinated alkyl compounds. Epigenetics. 2010;5:539–46.
49. Laird PW. Principles and challenges of genomewide DNA methylation
analysis. Nat Rev Genet. 2010;11:191–203.
50. Bock C. Analysing and interpreting DNA methylation data. Nat Rev Genet.
2012;13:705–19.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ramos et al. BMC Medical Genetics  (2016) 17:71 Page 6 of 6
